Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New kinasinib! Intense two-target formula kills cancer – Dead!

This article was originally published in Scrip

Executive Summary

The prospects of kinase inhibitors have been boosted by new research suggesting that by tweaking present treatment regimens, these drugs could further extend cancer survival beyond three to six months. With high doses of kinase inhibitors, a second, cytotoxic mechanism of action becomes apparent, with preclinical studies indicating enhanced cancer cell killing. With some 25 kinase inhibitors on the market and another 400 somewhere in development, the findings might buff up the commercial future of a whole important cancer drug class without additional huge clinical outlay.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts